DAPA HF: The Dapagliflozin And Prevention Of Adverse‑ outcomes In Heart Failure Trial
The aims of this study were to: (i) report the baseline characteristics of patients enrolled in the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial, (ii) compare DAPA-HF patients to participants in contemporary heart failure (HF) registries and in other recent HF trials, and (iii) compare individuals with diabetes, pre-diabetes and a normal glycated haemoglobin (HbA1c) in DAPA-HF.
Presenter:
John McMurray
Specialty:
Diabetes
EASD 2019